RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sutro Biopharma - Stock

Sutro Biopharma Stocks 2024

Sutro Biopharma Stocks

60.16 M

Ticker

STRO

ISIN

US8693671021

WKN

A2N6SG

In 2024, Sutro Biopharma had 60.16 M outstanding stocks, a 0% change from the 60.16 M stocks in the previous year.

The Sutro Biopharma Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e60.16
2028e60.16
2027e60.16
2026e60.16
2025e60.16
2024e60.16
202360.16
202250.74
202146.12
202032.57
201922.96
201822.85
201722.16
201622.16

Sutro Biopharma shares outstanding

The number of shares was Sutro Biopharma in 2023 — This indicates how many shares 60.164 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Sutro Biopharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Sutro Biopharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Sutro Biopharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Sutro Biopharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Sutro Biopharma Aktienanalyse

What does Sutro Biopharma do?

Sutro Biopharma Inc. is a biopharmaceutical company founded in 2003 by Dr. William James Sutro. The company is headquartered in South San Francisco, California and aims to develop biotech tools and platforms that accelerate and facilitate the manufacture of innovative therapeutics. Sutro Biopharma's business model focuses on creating drug candidates based on proprietary technologies. The company does not rely on conventional biological systems or cells typically used for protein expression and drug manufacturing. Instead, it has developed a platform for protein synthesis that allows for targeted and effective production of specific proteins. The main focus of Sutro Biopharma Inc. is cancer research and improved cancer therapy. Various business areas have been established for this purpose. In the field of oncology, Sutro Biopharma is involved in the development of immunotherapeutic agents such as bi-specific antibodies that are of interest for many types of cancer due to their high selectivity and efficacy. A special feature of Sutro Biopharma is the production of many therapeutic proteins as so-called conjugated proteins. This means that special bioactive molecules are attached to the surface of the therapeutic protein. These conjugated proteins enable targeted and enhanced drug effects. The STRO-001 program is an example of this type of conjugate and is one of the most promising products of Sutro Biopharma. STRO-001 is an antibody designed specifically for the recognition of tumor-associated CD74 proteins. These CD74 surface proteins are expressed by many cancer cells and therefore serve as ideal targets for cancer therapy. The STRO-001 antibody is delivered as a conjugate into the cancer cells, where it releases the toxic molecule calicheamicin, which ensures targeted destruction of the cancer cell. In addition to developing conjugated proteins for cancer research, Sutro Biopharma is also involved in combating autoimmune diseases such as rheumatoid arthritis. The XpressCF+ program has been launched for this purpose, which aims to facilitate the production of autoantibodies for novel therapeutics. Another division of Sutro Biopharma Inc. focuses on drug development for rare diseases. The company particularly focuses on proteolytic enzymes that could serve as targets for the development of new therapeutics for rare metabolic diseases. The goal is to expand the treatment options for many of these unexplored diseases through the development of innovative therapies. Overall, Sutro Biopharma Inc. has become an important company within the biotech industry in recent years, making significant contributions to cancer therapy and other serious diseases through its effective biotechnological tools and dedicated research efforts. The company is crucial in improving treatment possibilities for cancer and many other severe diseases. Sutro Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Sutro Biopharma's Shares Outstanding

Sutro Biopharma's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Sutro Biopharma’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Sutro Biopharma’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Sutro Biopharma’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Sutro Biopharma Stock

How many stocks are there of Sutro Biopharma?

The current number of stocks of Sutro Biopharma is 60.16 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Sutro Biopharma are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Sutro Biopharma evolved in recent years?

The number of shares of Sutro Biopharma has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Sutro Biopharma as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Sutro Biopharma?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Sutro Biopharma pay?

Over the past 12 months, Sutro Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sutro Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Sutro Biopharma?

The current dividend yield of Sutro Biopharma is .

When does Sutro Biopharma pay dividends?

Sutro Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Sutro Biopharma?

Sutro Biopharma paid dividends every year for the past 0 years.

What is the dividend of Sutro Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Sutro Biopharma located?

Sutro Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sutro Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sutro Biopharma from 6/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/29/2024.

When did Sutro Biopharma pay the last dividend?

The last dividend was paid out on 6/29/2024.

What was the dividend of Sutro Biopharma in the year 2023?

In the year 2023, Sutro Biopharma distributed 0 USD as dividends.

In which currency does Sutro Biopharma pay out the dividend?

The dividends of Sutro Biopharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sutro Biopharma

Our stock analysis for Sutro Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sutro Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.